Serotonin transporter gene variation and refractory mesial temporal epilepsy with hippocampal sclerosis

Epilepsy Res. 2009 Aug;85(2-3):231-4. doi: 10.1016/j.eplepsyres.2009.03.010. Epub 2009 Apr 16.


We performed a molecular epidemiology study in a population of 105 mesial temporal lobe epilepsy with hippocampal sclerosis (MTE-HS) patients in order to investigate the role of a polymorphism in the serotonin transporter gene (SLC6A4) in the prediction of antiepileptic drug (AED) treatment response. Homozygous carriers of the 12-repeat allele had an almost fourfold increase in risk for a MTE-HS not responding to medical treatment (OR 3.88; CI 95% 1.40-10.7; p=0.006) compared to carriers of the 10-repeat allele. Therefore, a polymorphism of SLC6A4 might be a genetic marker of pharmacoresistance in MTE-HS patients.

MeSH terms

  • Adult
  • Alleles
  • Anticonvulsants / therapeutic use
  • Drug Resistance
  • Epilepsy, Temporal Lobe / genetics*
  • Epilepsy, Temporal Lobe / pathology*
  • Female
  • Genetic Variation / genetics*
  • Genotype
  • Hippocampus / pathology*
  • Humans
  • Introns / genetics
  • Male
  • Minisatellite Repeats / genetics
  • Risk
  • Sclerosis
  • Serotonin Plasma Membrane Transport Proteins / genetics*


  • Anticonvulsants
  • SLC6A4 protein, human
  • Serotonin Plasma Membrane Transport Proteins